Financial Report: Merck 3Q

Merck 3Q

3Q Revenues: $6.0 billion (+2%)

3Q Earnings: $3.5 billion (earnings were $1.1 billion in 3Q08)

YTD Revenues: $17.3 billion (-3%)

YTD Earnings: $6.5 billion (+4%)

Comments: Singulair sales were $1.1 billion in the quarter (+5%). Combined global sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, were $1.0 billion (-7%). Global sales Cozaar and Hyzaar were $861 million in the quarter (-3%). Januvia sales were up 30% to $491 million. Gardasil sales were $311 million (-22%). R&D expenses were $1.3 billion for the quarter (+7). Restructuring costs, primarily related to employee separations, were $42 million for the quarter compared to $757 million in 3Q08.